Cargando...
Access to orphan drugs despite poor quality of clinical evidence
AIM: We analysed the Belgian reimbursement decisions of orphan drugs as compared with those of innovative drugs for more common but equally severe diseases, with special emphasis on the quality of clinical evidence. METHODS: Using the National Health Insurance Agency administrative database, we eval...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Blackwell Science Inc
2011
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3080635/ https://ncbi.nlm.nih.gov/pubmed/21395641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03877.x |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|